USP18 inactivating mutations in human individuals lead to severe type 1 interferonopathies through a lack of USP18-mediated negative regulation of the IFN signaling and thereby causing severe chronic inflammation, which predominantly affects the CNS, but also other organ systems including the heart (bradycardia) [32]. Here, USP18 is linked to type 1 interferonopathy.